Clinical and Pharmacokinetic Characteristics of Ziprasidone Single Versus Divided Dose Administration in Schizoaffective Disorder: A Casuistics

被引：0
|
作者：
Regenthal, Ralf [1 ]
Kuenstler, Ulf [2 ]
Fried, Franziska [2 ]
Teichert, Jens [1 ]
机构：
[1] Univ Leipzig, Inst Klin Pharmakol, D-04107 Leipzig, Germany
[2] Diakoniewerk Zschadrass gGmbH, Klin Psychiat Psychotherapie, D-04680 Zschadrass, Germany
来源：
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | 2009年 / 104卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：512 / 512
页数：1
相关论文
共 50 条
  • [1] Effect of ziprasidone dose on rates of medication discontinuation in acute schizophrenia or schizoaffective disorder
    Citrome, Leslie
    Yang, Ruoyong
    Harnett, James
    Glue, Paul
    Karayal, Onur
    BIOLOGICAL PSYCHIATRY, 2008, 63 (07) : 285S - 285S
  • [2] Effect of ziprasidone dose on rates of medication discontinuation in acute schizophrenia or schizoaffective disorder
    Karayal, O.
    Citrome, L.
    Yang, R.
    Harnett, J.
    Glue, P.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 160 - 160
  • [3] Improvement of comorbid depression with olanzapine versus ziprasidone treatment in patients with schizophrenia or schizoaffective disorder
    Kinon, BJ
    Lipkovich, I
    Edwards, SE
    Hill, AL
    Tollefson, GD
    BIOLOGICAL PSYCHIATRY, 2004, 55 : 185S - 186S
  • [4] Improvement of comorbid depression with olanzapine versus ziprasidone treatment in patients with schizophrenia or schizoaffective disorder
    Kinon, BJ
    Lipkovich, I
    Edwards, SE
    SCHIZOPHRENIA BULLETIN, 2005, 31 (02) : 491 - 491
  • [5] Improvement of comorbid depression with olanzapine versus ziprasidone treatment in patients with schizophrenia or schizoaffective disorder
    Kinon, B
    Lipkovich, I
    Edwards, S
    Hill, A
    Ahl, J
    SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 163 - 163
  • [6] Bipolar versus schizoaffective disorder: Clinical profiles
    Romosan, A. M.
    Dehelean, L.
    Romosan, R. S.
    Papava, I.
    Drut, I.
    EUROPEAN PSYCHIATRY, 2017, 41 : S426 - S427
  • [7] Efficacy of ziprasidone in the treatment of schizoaffective disorder: An analysis of 2 fixed dose, placebo-controlled trials
    Warrington, L.
    Loebel, A.
    Lombardo, I.
    Yang, R.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S278 - S278
  • [8] Effects of High-Dose Ziprasidone and Haloperidol on the QTc Interval After Intramuscular Administration: A Randomized, Single-Blind, Parallel-Group Study in Patients With Schizophrenia or Schizoaffective Disorder
    Miceli, Jeffrey J.
    Tensfeldt, Thomas G.
    Shiovitz, Thomas
    Anziano, Richard J.
    O'Gorman, Cedric
    Harrigan, Rachel H.
    CLINICAL THERAPEUTICS, 2010, 32 (03) : 472 - 491
  • [9] Efficacy of ziprasidone in the treatment of schizoaffective disorder: An analysis of two fixed dose, placebo-controlled trials
    Warrington, Lewis
    Lombardo, Ilise
    Loebel, Antony
    Rappard, Fred
    Yang, Ruoyong
    BIPOLAR DISORDERS, 2006, 8 : 36 - 37
  • [10] Investigation of sociodemographic and clinical characteristics of patients with schizoaffective disorder
    Virit, Osman
    Kokacya, Mehmet Hanifi
    Bulbul, Feridun
    Citak, Serhat
    Savas, Haluk Asuman
    ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY, 2009, 10 (03): : 204 - 211
12345